Analyst Opinion Summary: Amneal Pharmaceuticals, Inc. (AMRX), Sea Limited (SE)

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) tinted gains of +2.39% (+0.3 points) to US$12.87. The volume of 0.46 Million shares climbed down over an trading activity of 942.02 Million shares. EPS ratio determined by looking at last 12 month figures is -4.28. Over the same time span, the stock marked US$24.48 as its best level and the lowest price reached was US$11.66. The corporation has a market cap of US$3.86 Billion.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s earnings per share has been growing at a -58.5 percent rate over the past 5 year when average revenue increase was noted as 5.9 percent. The return on equity ratio or ROE stands at -156 percent while most common profitability ratio return on investment (ROI) was -43.4 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -23.2 percent and possesses 39.7 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 7 think it is Hold. Recently, analysts have updated the overall rating to 2.45. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Sea Limited (NYSE:SE) is worth US$4.87 Billion and has recently risen 2.37% to US$15.1. The latest exchange of 2.16 Million shares is above its average trading activity of 1.53 Million shares. The day began at US$14.75 but the price moved to US$14.51 at one point during the trading and finally capitulating to a session high of US$15.2. The stock tapped a 52-week high of US$17.19 while the mean 12-month price target for the shares is US$17.83.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 215.71, and a price to sales ratio of 7.29. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 59.3%, it carries an earnings per share ratio of -2.77.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 7 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.78.